Movement Disorders Clinical Trials

Find Movement Disorders Clinical Trials Near You

Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this clinical trial is two-fold. First to investigate the feasibility of whether a remotely administered smartphone app can increase the volume and intensity of physical activity in daily life in individuals with a LRRK2 G2019S or GBA1 N370S genetic mutation over a long period of time (24 months). Second, to explore the preliminary efficacy of exercise on markers for prodromal Parkinson's disease progression in individuals with a LRRK2 G2019S or GBA1 N370S genetic mutation. Participants will be tasked to achieve an incremental increase of daily steps (volume) and amount of minutes exercised at a certain heart rate (intensity) with respect to their own baseline level. Motivation with regards to physical activity will entirely be communicated through the study specific Slow Speed smartphone app. A joint primary objective consists of two components. First to determine the longitudinal effect of an exercise intervention in LRRK2 G2019S or GBA1 N370S variant carriers on a prodromal load score, comprised of digital biomarkers of prodromal symptoms. The secondary component of the primary outcome is to determine the feasibility of a remote intervention study. The secondary objective is the effect of a physical activity intervention on digital markers of physical fitness. Exploratory outcomes entail retention rate, completeness of remote digital biomarker assessments, digital prodromal motor and non-motor features of PD. Using these biomarkers, the investigators aim to develop a composite score (prodromal load score) to estimate the total prodromal load. An international exercise study with fellow researchers in the United Kingdom are currently in preparation (Slow-SPEED-UK) and active in the Netherlands (Slow-SPEED-NL). Our intention is to analyse overlapping outcomes combined where possible through a meta-analysis plan, to obtain insight on (determinants of) heterogeneity in compliance and possible efficacy across subgroups

Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Healthy Volunteers: f
View:

• previously identified LRRK2 G2019S or GBA N370S variant based on genotyping

• aged 50 years or older

• able to understand the English language

• being able to walk independently inside the home without the use of a walking aid

• in possession of a suitable smartphone (screen size minimum 4.6 inch), (Android version 9 or iOS version 15 or newer)

• Not in a high physical activity range during the 4-week eligibility and baseline period

Locations
United States
New York
University of Rochester Center for Health and Technology (CHeT)
RECRUITING
Rochester
Other Locations
Netherlands
Radboud University Medical Center
NOT_YET_RECRUITING
Nijmegen
Contact Information
Primary
Thomas Oosterhof, MSc
thomas.oosterhof@radboudumc.nl
0031631647857
Time Frame
Start Date: 2025-09-01
Estimated Completion Date: 2029-06-30
Participants
Target number of participants: 600
Treatments
Experimental: Large increase in step count and moderate to vigorous physical activity relative to baseline level.
Active_comparator: Small increase in step count and moderate to vigorous physical activity relative to baseline level.
Related Therapeutic Areas
Sponsors
Collaborators: University of Rochester, Parkinson's UK, IJsfontein B.V., Netherlands, Massachusetts General Hospital, University of Luebeck, Davis Phinney Foundation, Michael J. Fox Foundation for Parkinson's Research, University of Pittsburgh, Sleep Medicine Centre Kempenhaeghe, Sleep Medicine Centre SEIN, University of Bristol, Parkinson's Foundation, Erasmus Medical Center, University of Plymouth, ZonMw: The Netherlands Organisation for Health Research and Development, Stichting ParkinsonNL, Hoffmann-La Roche, Queen Mary University of London, Parkinsons Progression Markers Initiative (PPMI), 23andMe, Inc., Harvard School of Public Health (HSPH), McGill University, Cure Parkinson's, University of Illinois at Chicago, Edmond J. Safra Foundation, Donders Centre for Cognitive Neuroimaging
Leads: Radboud University Medical Center

This content was sourced from clinicaltrials.gov